VAV3 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 18 and 1 bp insertion in exon 18.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 18 and 1 bp insertion in exon 18.
Alternative names
FLJ40431, Guanine nucleotide exchange factor VAV3, Protein vav 3, RGD1565941, VAV 3 oncogene, VAV 3 protein, VAV3_HUMAN, Vav 3 guanine nucleotide exchange factor
What's included?
Recommended products
VAV3 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 18 and 1 bp insertion in exon 18.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 18 and 1 bp insertion in exon 18.
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- VAV3
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
The VAV3 protein also known as the guanine nucleotide exchange factor VAV3 functions as a regulator of Rho family GTPases by promoting the exchange of GDP for GTP. It weighs approximately 101 kDa and exhibits expression in various tissues including the brain heart and hematopoietic cells. VAV3 serves as an important modulator within the intracellular signaling processes by influencing actin cytoskeletal dynamics and impacting cellular morphology and movement.
- Biological function summary
VAV3 influences multiple cellular processes like cell proliferation differentiation and migration. Part of many signaling complexes VAV3 interacts with receptors on the cell surface transmitting signals inside the cell. These interactions play a role in the regulation of immune responses and its involvement in the nervous system aids in neuron development and connectivity.
- Pathways
VAV3 takes part in the regulation of the Rho GTPase pathway and the phosphoinositide 3-kinase (PI3K) pathway. VAV3 cooperates with proteins such as RAC1 and CDC42 influencing these pathways to modulate cell survival cytoskeleton rearrangement and membrane trafficking. Interaction with PI3K pathway components amplifies signals for growth factor-induced cellular responses impacting the overall cell function and homeostasis.
- Associated diseases and disorders
VAV3 influences both cancer and autoimmune diseases due to its regulatory role in cell signaling. Overexpression or abnormal regulation of VAV3 relates to prostate cancer progression and metastasis through its interaction with androgen receptor signaling pathways. In autoimmune diseases VAV3's interaction with proteins such as SYK can affect the severity of conditions like rheumatoid arthritis by modulating immune cell activation and response.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Western blot - Human VAV3 knockout HeLa cell lysate (ab258280)
Lane 1: Wild-type HeLa cell lysate 20 μg
Lane 2: Empty
Lane 3: VAV3 knockout HeLa cell lysate 20 μg
False colour image of Western blot: Anti-VAV3 antibody [EP1130Y] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-VAV3 antibody [EP1130Y] ab52938 was shown to bind specifically to VAV3. A band was observed at 98 kDa in wild-type HeLa cell lysates with no signal observed at this size in VAV3 knockout cell line Human VAV3 knockout HeLa cell line ab265419 (knockout cell lysate ab258280). To generate this image, wild-type and VAV3 knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 5 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.Lanes 1 and 3: Western blot - Anti-VAV3 antibody [EP1130Y] (Anti-VAV3 antibody [EP1130Y] ab52938) at 1/1000 dilution
Lane 2: Western blot - Anti-VAV3 antibody [EP1130Y] (Anti-VAV3 antibody [EP1130Y] ab52938)
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: Empty
Lane 2: Western blot - Human VAV3 knockout HeLa cell line (Human VAV3 knockout HeLa cell line ab265419)
Lane 3: VAV3 knockout HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 98 kDa
Observed band size: 98 kDa
Sanger Sequencing - Human VAV3 knockout HeLa cell lysate (ab258280)
Allele-1: 1 bp deletion in exon 18
Sanger Sequencing - Human VAV3 knockout HeLa cell lysate (ab258280)
Allele-2: 1 bp insertion in exon 18
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com